Procter & Gamble investors have a fresh reason to scrutinize the gap between top-line momentum and bottom-line delivery. Zacks Research cut its earnings per share estimate for the company’s fiscal 2027 second quarter to $1.80 from $1.88, a revision that lands barely two weeks after the consumer goods giant posted results that beat expectations on both revenue and adjusted profit.
The downgrade puts the durability of P&G’s earnings growth squarely in the spotlight. For the full fiscal year 2027, Zacks now models $6.96 per share, a touch below the analyst consensus of $6.99. That the annual figure sits only marginally under the market’s average suggests the house is not abandoning its constructive stance — but the trimmed quarterly number signals caution about how much of the recent operating strength will survive higher costs in the current period.
A Strong Opening Quarter Sets the Bar
The backdrop is a fiscal first quarter that came in ahead of forecasts. P&G reported adjusted earnings of $2.00 per share on October 22, against analyst expectations of $1.89. Net sales reached $23.28 billion versus a projected $22.80 billion, a 4% increase over the prior-year quarter. Organic sales growth for the period also came in at 4%, giving investors a concrete growth figure to track.
Those numbers give the bullish case real substance: the revenue beat was not an accounting quirk but reflected genuine volume and pricing gains. The question now is conversion — whether that growth can be translated into profit once the additional cost burden is absorbed.
Costs Loom Over the Outlook
Management has flagged substantial incremental expenses, driven in large part by the Middle East conflict. For fiscal 2027, the company pegs the after-tax hit at roughly $1.4 billion, an estimate that assumes a Brent crude price of $100 per barrel. Notably, the outlook does not bake in any further significant cost increases — meaning the guidance rests on an assumption that commodity prices hold roughly where they are.
The margin pressure was already visible in the opening quarter. Gross margin slipped to 49.8% from 51.4% a year earlier. Higher sales broaden the earnings base, but only to the extent that enough profit remains after the extra outlays.
Against that squeeze, P&G reaffirmed its full-year adjusted EPS guidance of $6.89 to $7.11. Hitting that range will require growth to generate sufficient earnings power to offset the cost headwinds — the central test for the coming quarters.
Should investors sell immediately? Or is it worth buying Procter & Gamble?
Two Scenarios, One Decisive Variable
The optimistic path rests on the operating start. If organic growth holds near its current pace and management can demonstrate how the announced transformation links growth to profitability, the confirmed annual guidance would look well within reach — and the softer quarterly estimate from Zacks would fade in significance relative to actual business performance.
The cautious path hinges on the combination of commodity pressure and the lowered quarterly view. Should sales growth decelerate or yield less profit than hoped, the full-year target becomes more demanding, and the strong opening quarter loses its persuasive force. Investors would then need to watch whether cost headwinds constrain earnings power over a longer stretch. A convincing strategic narrative, in that case, would be judged by later execution rather than presentation.
November 19 Investor Day in Focus
The next scheduled milestone is P&G’s investor day on November 19, webcast from 2 p.m. US Eastern time. CEO Shailesh Jejurikar, CFO Andre Schulten and the broader leadership team are set to discuss strategy and the transformation program.
What investors will listen for is the connective tissue: how strategic initiatives, cost pressure and future earnings fit together. A clear explanation of how further growth becomes durable profit would add weight to the positive case. A vaguer link between transformation and earnings targets would let the lowered quarterly estimate carry more influence over valuation.
January Report Becomes the Real Scorecard
The second quarter, which runs through the end of December, is expected to bring markedly higher costs, making the January 2027 earnings release the key checkpoint for the revised Zacks number. Gross margin will be the metric to watch. Stabilization despite the added expense would support the earnings outlook; a further decline alongside rising costs would put the annual targets under greater strain. In the end, operational execution — not the estimate revision itself — will determine whether the guidance holds.
Ad
Procter & Gamble Stock: Buy or Sell?! New Procter & Gamble Analysis from November 7 delivers the answer:
The latest Procter & Gamble figures speak for themselves: Urgent action needed for Procter & Gamble investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 7.
Procter & Gamble: Buy or sell? Read more here...
